share_log

Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5

Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics With Overweight Rating, Announces Price Target of $5

坎托·菲茨杰拉德以增持评级开始对Atossa Therapeutics进行保险,宣布目标股价为5美元
Benzinga ·  2023/09/08 08:16

Cantor Fitzgerald analyst Louise Chen initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Overweight rating and announces Price Target of $5.

坎托·菲茨杰拉德分析师路易丝·陈以增持评级开始对Atossa Therapeutics(纳斯达克股票代码:ATOS)进行报道,并宣布目标股价为5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发